WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · LC 2725

Legislative bill overview

LC 2725 would expand Montana's "right to try" law to permit minors diagnosed with terminal illnesses to access unapproved experimental medications and treatments that have completed early-stage clinical trials. Currently, right to try laws typically apply only to adults, creating a legal gap for dying children whose parents seek experimental options when standard treatments have been exhausted.

Why is this important

This addresses a genuine ethical dilemma: parents of terminally ill children face legal barriers when seeking last-resort experimental therapies that might extend or improve their child's life. The issue balances compassion for desperate families against regulatory safety frameworks designed to protect vulnerable populations from unproven treatments.

Potential points of contention

  • Informed consent complexity: Minors cannot legally consent to experimental treatment; the bill would rely on parental consent, raising questions about adequacy of protections for children who cannot advocate for themselves
  • Safety vs. desperation: While early-stage trials have safety data, children are biologically different from adult trial participants; expanding access could expose minors to poorly-understood risks when hope overrides judgment
  • Liability and manufacturer involvement: Unclear whether pharmaceutical companies would participate in providing unapproved drugs to minors without liability protections, potentially limiting practical access despite legal permission

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.